GlassScriptPhysician profile
Kevin A Kahn
NPI 1013088350
$587,473.53
in general payments reported to CMS, 2019-2025
41 companies · $78K in 2025
The $78K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113K · 2020: $68K · 2021: $129K · 2022: $103K · 2023: $72K · 2024: $24K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122K · Honoraria: $24K · Travel and Lodging: $12K · Food and Beverage: $9,904 · Consulting Fee: $7,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,745.00 |
| Honoraria | $23,564.00 |
| Travel and Lodging | $11,919.79 |
| Food and Beverage | $9,903.76 |
| Consulting Fee | $7,225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $196,224.84 | 2021-2025 | |
| Amgen INC. | $109,510.58 | 2019-2024 | Aimovig |
| Lilly USA, LLC | $67,464.59 | 2019-2025 | Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $58,570.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $54,127.14 | 2019-2025 | Ajovy |
| Axsome Therapeutics, INC. | $29,046.19 | 2024-2025 | Symbravo |
| Allergan, INC. | $25,075.74 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $22,687.68 | 2022-2023 | Trudhesa |
| Pfizer INC. | $12,606.00 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,832.39 | 2022 | |
| Biodelivery Sciences International, INC. | $3,013.74 | 2019-2021 | |
| Lundbeck LLC | $926.91 | 2020-2025 | Vyepti |
| Upsher-Smith Laboratories LLC | $846.28 | 2019-2023 | |
| Impel Pharmaceuticals LLC | $376.49 | 2024-2025 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $362.52 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.